Moderna, Inc.

🇺🇸NASDAQ Global Select

Articles

60
Show Summary
Show Bulletpoints
Detailed View
Slightly Bearish -15

How Will Moderna Stock React To Its Upcoming Earnings? - Trefis

📅 Moderna earnings scheduled for Friday, May 1, 2026.

💰 Revenue hit $1.9B last twelve months with operational losses.

⚠ Diversified portfolios recommended over single stock picking.

🏆 Trefis High Quality Portfolio beats major benchmarks consistently.

🌍 ON Semiconductor gained 57% while Lockheed Martin dropped 15%.

📅 Moderna is scheduled to report earnings on Friday, May 1, 2026.

💰 The company currently has a market capitalization of $18 billion.

📉 Recent financial data shows $1.9 billion in revenue over the last twelve months.

❗ The company reported operational losses of $3.1 billion and net income of $2.8 billion.

📊 Analysts suggest trading strategies based on historical post-earnings returns.

🔍 Traders can analyze correlations between one-day, five-day, and twenty-one-day returns.

💡 A strategy involves identifying high correlation periods to position trades for the next five days if one-day returns are positive.

⚠️ Stock picking may fail even with a good strategy without diversification.

🏆 The Trefis High Quality Portfolio offers a diversified approach using 30 stocks.

📈 The HQ Portfolio track record shows outperformance against S&P 500, mid-cap, and Russell 2000 benchmarks.

🎢 This diversified portfolio aims to reduce risk compared to individual stock volatility.

🌍 Other market movers include ON Semiconductor rising 57% and Lockheed Martin dropping 15%.

Bullish Signals
  • Moderna to report earnings May 1, 2026, an upcoming investor catalyst.
  • Trefis High Quality Portfolio offers upside with diversified 30-stock holdings outperforming benchmarks.
  • ON Semiconductor rose 57% with a 14-day winning streak.
  • Amkor Technology stock jumped 22% on a 6-day winning streak.
  • Cummins Stock climbed 9.2% amid a 6-day winning spree.
Risk Factors
  • Moderna operationally loss-making with $3.1B operating losses and $2.8B net income.
  • Market cap of $18B far exceeds last 12 months revenue of $1.9B, suggesting high valuation.
  • Stock reaction heavily depends on meeting investor expectations, creating significant trader risk.
  • Stock picking can fail regardless of strategy due to inherent volatility and unpredictability.
Bullish Signals
  • Moderna is set to report earnings on Friday, May 1, 2026, providing an upcoming catalyst for investors.
  • The Trefis High Quality Portfolio offers a way to achieve upside with a smoother ride by diversifying across 30 stocks that collectively outperform the S&P 500, S&P mid-cap, and Russell 2000 benchmarks.
  • ON Semiconductor demonstrated strong momentum with a 57% surge and a 14-day winning streak, showcasing positive market sentiment in the sector.
  • Amkor Technology Stock Rockets 22% With 6-Day Winning Streak.
  • Cummins Stock enjoyed a 6-Day Winning Spree, climbing 9.2%, indicating robust performance among portfolio constituents.
Risk Factors
  • Moderna is operationally loss-making with significant $-3.1 Bil in operating losses and $-2.8 Bil net income, raising concerns about long-term profitability.
  • The company's current market capitalization of $18 Billion significantly outweighs its last twelve months' revenue of $1.9 Billion, suggesting a high valuation relative to earnings potential.
  • Historical post-earnings return data shows that Moderna stock reaction depends heavily on meeting investor expectations, creating significant risk for traders if results disappoint.
  • The article emphasizes stock picking can fail regardless of strategy, highlighting the inherent volatility and unpredictability associated with individual stock trades like MRNA.
Bearish -65

Moderna Stock Slides -18% With A 5-Day Losing Spree - Trefis

📉 Moderna stock fell 18%, causing a $3.9 billion market cap drop.

⚠ Analysts recommend selling due to high valuation concerns despite recent losses.

🏆 Trefis High Quality Portfolio outperforms benchmarks with lower risk and volatility.

🔒 Using predictive signals helps mitigate stock-specific drawdowns before news headlines.

📉 Moderna stock experienced an 18% decline over a five-day period, resulting in a $3.9 billion drop in market capitalization.

💰 The current market cap of Moderna stands at approximately $18 billion following the recent losses.

⚠️ Investors cite weak operating performance and financial condition as reasons to fear the stock.

📉 Analysts recommend a sell rating due to concerns over Very High valuation despite the price drop.

📊 Historical analysis suggests managing individual stock risk requires predictive signals rather than waiting for news headlines.

📈 Comparative data shows 92 S&P constituents have endured three or more days of consecutive losses, while only 33 have had gains.

🏆 Trefis High Quality Portfolio outperforms benchmarks including the S&P 500 with lower risk and reduced volatility.

🔒 The article advocates using predictive signals to mitigate stock-specific drawdowns before market movements occur.

💸 Other recent market movers include ON Semiconductor surging 57% and Lockheed Martin plummeting 15%.

📉 Small-cap, mid-cap, and large-cap stocks are tracked for their performance relative to 52-week highs and lows.

Bullish Signals
  • Moderna operates in high-growth biotech with significant upside potential.
  • Stock maintains $18B market cap despite recent volatility.
Risk Factors
  • Stock down 18% over last 5 trading days.
  • Market cap dropped $3.9 billion to $18 billion.
  • Analysts warn weak performance and poor financial condition.
  • Very high valuation makes stock unattractive.
  • Among 92 S&P constituents on losing streaks.
Bullish Signals
  • Moderna's mRNA-based therapeutics and vaccines position it within a high-growth biotechnology sector with significant future upside potential.
  • Despite recent volatility, the stock has maintained a market cap of $18 Bil, indicating continued investor interest in its technology platform.
Risk Factors
  • Moderna stock has experienced a cumulative decline of -18% over the last 5 trading days, reflecting a 5-day losing streak that lacks investor confidence.
  • The company's market cap has crashed by approximately $3.9 billion in this short period, now sitting at only $18 billion valuation.
  • Analysts warn of Weak operating performance and a poor financial condition as significant risks for the stock's long-term prospects.
  • Despite the price drop, the company retains a Very High valuation which makes it considered Very Unattractive to current investors.
  • Moderna is currently among 92 S&P constituents that are on streaks of 3 or more consecutive losses, indicating broader market weakness.
Very Bearish -75

Moderna Stock Slides -18% With A 5-Day Losing Spree - Trefis

📉 Moderna dropped 18% over five days, reducing market cap by $3.9B to $18B.

⚠ Selling driven by weak fundamentals and high valuation concerns relative to earnings.

🔄 Recent declines align with broader S&P losses while High Quality Portfolio outperforms.

📉 Moderna (MRNA) experienced an 18% cumulative stock decline over a 5-day period.

💸 The company's market cap dropped by approximately $3.9 billion during this losing streak.

💰 Current valuation stands at $18 billion following the significant drop in share price.

⚠️ Investors cite weak operating performance and financial condition as reasons for selling pressure.

📊 High valuation relative to fundamentals makes the stock appear unattractive to analysts.

📈 Historical dip analysis is recommended to determine if previous downturns were buying opportunities.

🔍 Market participants note that negative headlines have already been priced into the stock price.

🛡️ Predictive risk models are suggested for managing stock-specific drawdowns before news hits.

🏆 The High Quality (HQ) Portfolio track record shows outperformance with less volatility than the benchmark.

📊 There are currently 92 S&P constituents with 3 or more consecutive days of losses.

🔄 Several other S&P 500 stocks like Lockheed Martin and Cummins recently saw significant price swings.

🏢 Large, mid, small, and large cap stocks across the market are mixed in their 52-week trading positions.

📉 The losing streak for MRNA contrasts with the performance of the High Quality Portfolio group.

Risk Factors
  • Stock lost 18% in 5 days.
  • Market cap crashed $3.9B in 5 days.
  • Analysts cite weak performance and deterioration.
  • Valuation appears too high vs fundamentals.
Risk Factors
  • Moderna (MRNA) stock hit a 5-day losing streak with cumulative losses amounting to -18%, indicating sustained downward pressure.
  • The company's market cap has crashed by about $3.9 billion over the last 5 days, with current valuation standing at only $18 billion.
  • Analysts highlight Moderna's overall weak operating performance and deteriorating financial condition as primary concerns for investors.
  • The stock is described as having a very high valuation relative to its fundamentals, making it deemed very unattractive by the analysts.
Somewhat Bearish -47

Moderna Stock 5-Day Losing Spree: Stock Falls 18% - Trefis

📉 Moderna stock fell 18% over five days as market cap dropped $3.9B.

⚠ Analysts cite weak performance and high valuation making it unattractive.

🔍 S&P constituents face similar loss streaks despite news already priced in.

💰 High quality portfolios outperform benchmarks with less risk and volatility.

📉 Moderna (MRNA) stock experienced its fifth consecutive day of losses, with cumulative shares dropping approximately 18% over the period.

💸 The company's market capitalization fell by around $3.9 billion during the same timeframe to reach $18 billion.

⚠️ Analysts characterize Moderna as unattractive due to weak operating performance and a combination of poor financial condition with high valuation.

📊 Market sentiment suggests that this specific downturn has already been priced in by investors prior to recent headlines.

🔍 Trefis notes that 92 S&P constituents are currently experiencing streaks of three or more consecutive days of losses.

💰 In contrast, Trefis' High Quality Portfolio is outperforming benchmark indices like the S&P 500 with less risk and volatility.

🤖 The article suggests using predictive risk models to manage individual stock drawdowns rather than reacting to news notifications.

Bullish Signals
  • Moderna stock trades at $18B market cap after declining.
  • High Quality Portfolio outperformed major S&P and Russell benchmarks.
  • Market priced in recent Moderna news, hinting at upside.
Risk Factors
  • Stock fell 18% over five days with a $3.9 billion market cap loss.
  • Weak performance and high valuation make shares very unattractive.
  • No positive news counters recent declines or ongoing uncertainty.
Bullish Signals
  • Moderna stock currently trades at a market capitalization of $18 billion, suggesting the price has already adjusted significantly following recent declines.
  • High Quality Portfolio demonstrates a track record of comfortably outperforming its benchmark across S&P 500, S&P mid-cap, and Russell 2000 indices, providing a model investors can consider for managing stock-specific drawdowns.
  • The article indicates that the market has already priced in recent negative news regarding Moderna, implying potential stabilization or further upside if fundamentals improve.
Risk Factors
  • Moderna (MRNA) stock hit a 5-day losing streak with cumulative losses amounting to -18% and the company market cap has crashed by about $3.9 billion over this period.
  • The article highlights fears regarding Moderna's weak operating performance and financial condition, making the stock Very Unattractive given its very high valuation.
  • There are no positive news to counterbalance the recent -18% move, suggesting the market has already priced in negative developments but investors remain exposed to ongoing uncertainty.
Slightly Bullish +25

Moderna (MRNA) Reports Earnings Tomorrow: What To Expect - StockStory

📅 Moderna reports earnings this Friday morning after last quarter beat revenue despite decline.

🎯 Analysts expect 131% YoY revenue growth this quarter, reversing previous downward trend.

⚠ Sentiment is bearish with recent price target ($41.42) below current stock price ($45.54).

📅 Moderna is scheduled to report quarterly earnings results this Friday morning.

💰 Last quarter, the company beat revenue expectations with $678 million reported despite a 29.8% year-on-year decrease.

🎯 This quarter, analysts expect revenue to grow significantly by 131% year on year, reversing last year's decline.

⚠️ Analyst sentiment is increasingly bearish with downward revenue revisions over the past 30 days.

🤝 Peers like Biogen and AbbVie reported their Q1 results recently, providing some market context for comparisons.

📉 Investors have shown mixed sentiment in the biotech sector, with Moderna down 10.4% this month while peers gained 6.4%.

💵 The average analyst price target is $41.42, which is below the current stock price of $45.54.

📜 The company has a history of rarely missing Wall Street's revenue estimates historically.

Bullish Signals
  • Moderna beat analysts' revenue with $678 million and strong EPS.
  • Revenue grew 131% YoY, reversing last year's 35.3% decline.
  • Rarely misses Wall Street estimates, showing consistent operational strength.
Risk Factors
  • Revenue dropped 29.8% year on year.
  • Analysts revised revenue estimates down over 30 days.
  • Stock down 10.4% month amid biotech gains of 6.4%.
  • Price $45.54 above target $41.42 risks downside.
  • Revenue expected to rise 131% may not materialize.
Bullish Signals
  • Moderna beat analysts' revenue expectations last quarter, reporting revenues of $678 million with a beat of analysts' EPS and revenue estimates.
  • Market expectations for this quarter show Moderna's revenue growing 131% year on year, representing a significant reversal from the 35.3% decrease recorded in the same quarter last year.
  • Moderna rarely misses Wall Street's revenue estimates, indicating consistent operational strength despite broader market headwinds.
Risk Factors
  • Moderna's revenue dropped 29.8% year on year, despite beating estimates last quarter.
  • Analysts have grown increasingly bearish with majority downward revisions to revenue estimates over the last 30 days.
  • The stock is down 10.4% over the last month compared to the broader biotechnology segment which rose 6.4%.
  • Current share price of $45.54 trades above the average analyst price target of $41.42, suggesting potential downside if earnings are missed.
  • Last quarter's revenue growth was 35.3% decline, with market now expecting a strong 131% reversal which may not materialize given peer performance like Biogen beating expectations by only 11.2% or AbbVie missing estimates by 5.2%.
Neutral 0

Moderna Earnings Notes - Trefis

📅 Page updated 4/29/2026 for Moderna's 2025 Q4 earnings results.

❌ Growth metrics excluded due to negative financial bases.

⚠ Market data delayed 15-20 minutes across major exchanges.

📅 The page was last updated on 4/29/2026 regarding Moderna's 2025 Q4 earnings results.

📉 Growth figures for Operating Income, Net Income, and EPS are not calculated due to negative bases that make the numbers meaningless.

💼 Earnings reaction data is displayed through market history and interactive models powered by Quotemedia.com.

⚠️ Financial market data shown on the site is delayed by 20 minutes for NYSE/AMEX and 15 minutes for NASDAQ.

🤖 The interactive model includes specific limits on modifying drivers within a single scenario.

🔒 Some scenario drivers cannot be modified because they are linked to parent scenarios that have already changed them.

⚖️ Users agree to the Terms of Use upon accessing the site, which is owned by Insight Guru Inc.

Bullish Signals
  • Moderna reported Q4 2025 earnings showing continued investor interest.
  • Despite missing metrics, stock trades on NYSE/AMEX with real-time data.
Risk Factors
  • Article contains no actual earnings data or fundamentals.
  • Operating income and EPS growth metrics are missing.
  • Data delays up to 20 minutes may impact trading decisions.
  • Driver limits restrict scenario analysis flexibility.
  • Some driver values have minimum or maximum limits.
  • Scenario drivers linked to parent scenarios cannot be changed.
  • Earnings history lacks specific numerical performance metrics.
  • Website access requires Terms of Use agreement.
  • Market reaction history section provides no stock insights.
  • Data may be future-dated rather than historical actuals.
Bullish Signals
  • Moderna (MRNA) recently reported Q4 2025 earnings results, indicating continued market activity and investor interest in the company.
  • Despite some financial metrics being unavailable due to negative base effects, Moderna maintains a presence on major exchanges including NYSE/AMEX with available real-time data feeds for tracking performance.
Risk Factors
  • The article contains no actual earnings data or fundamental business information about Moderna, consisting only of website interface text and disclaimers.
  • Operating Income Growth, Net Income Growth, and EPS Growth results are missing due to negative bases, making these key metrics meaningless for analysis.
  • Data delays up to 20 minutes (NYSE/AMEX) and 15 minutes (NASDAQ) could impact real-time trading decisions based on reported earnings.
  • The interactive model has a limit on the number of drivers that can be modified in a single scenario, limiting scenario analysis flexibility.
  • Some driver values have minimum or maximum limits which may restrict custom financial modeling for analysts.
  • Scenario data is linked to a parent scenario where certain drivers are already modified and cannot be changed within the current view.
  • The earnings result history lacks specific numerical performance metrics as it only references historical observation without providing the actual consolidated view data.
  • Website usage requires agreement to Terms of Use, indicating potential legal compliance obligations for accessing financial market data.
  • Market reaction history section provides no specific content, offering no insight into stock price movements or investor sentiment surrounding recent earnings releases.
  • The copyright notice indicates the content is from Insight Guru Inc. dated 4/29/2026, which may represent future-dated or simulated data rather than historical actuals.
Neutral 0

Moderna Gears Up to Report Q1 Earnings: Here's What to Expect - Yahoo Finance

📅 Moderna reports Q2 earnings on May 1, with analysts expecting sales up but EPS losses shrinking from prior year.

💊 Revenue focused on COVID vaccines while EU approved new mCombriax flu/COVID combination therapy for launch later in year.

🔬 Pipeline includes 30+ candidates plus Merck collaboration intismeran, though shares rallied 65% YTD despite current analyst skepticism.

📅 Moderna is scheduled to report its first-quarter 2026 earnings on May 1, before the opening bell.

📉 Analysts expect sales of $223.5 million and a loss of $2.29 per share, showing improvement from the prior year.

💊 Sales will likely be driven primarily by two COVID-19 vaccines (Spikevax and mNexspike) with minimal revenue from the RSV vaccine (mResvia).

🌍 The EU approved Moderna’s mCombriax combination vaccine for COVID-19 and influenza earlier this month, adding to its portfolio.

💉 mCombriax builds on successful late-stage data for its standalone flu shot component which showed superior efficacy against GSK’s vaccine.

🧬 Investors will focus on updates regarding the commercialization timeline of mCombriax and the FDA resubmission status.

🔬 Moderna is developing more than 30 mRNA-based investigational candidates across various clinical stages, including cancer therapies.

🤝 A key pipeline candidate is intismeran autogene, a personalized cancer therapy developed in collaboration with Merck for multiple indications.

📊 Moderna has beaten earnings estimates in each of the trailing four quarters with an average surprise of 34.40%.

📈 Shares have rallied 65% year to date compared to the industry’s 1% decline.

⚠️ The company currently carries a Zacks Rank #3 and an Earnings ESP of -25.75%, suggesting analysts do not expect a beat this time.

Bullish Signals
  • Moderna beat estimates by 18.85%, indicating strong performance ahead of Q1 2026 earnings.
  • Company has achieved earnings beats in each of the trailing four quarters.
  • Shares rallied 65% year to date, significantly outperforming industry decline.
  • Moderna secured EU approval for mCombriax, expanding portfolio to four marketed products.
  • Flu shot mRNA-1010 showed superior efficacy compared with GSK's approved vaccine.
  • Moderna develops more than 30 mRNA-based candidates across various clinical stages.
  • Intismeran autogene evaluated in three phase III studies for cancer therapy.
Risk Factors
  • Competition from GSK and Pfizer limits RSV vaccine sales expectations.
  • Analysts forecast earnings loss of $2.87 per share.
  • Stock rallied 65% year to date, inflating valuations ahead of earnings.
  • FDA resubmission concerns linger after mCombriax filing withdrawal.
  • Earnings ESP at -25.75% lowers probability of beating estimates.
  • Zacks Rank #3 indicates limited analyst confidence in stock.
  • mCombriax faces commercialization uncertainty after efficacy data requests.
Bullish Signals
  • Moderna beat earnings estimates by 18.85% in the last reported quarter, indicating strong performance ahead of its Q1 2026 earnings report on May 1.
  • The company has achieved an impressive track record with earnings beats in each of the trailing four quarters and an average surprise of 34.40%.
  • Moderna's shares have rallied 65% year to date, significantly outperforming the industry's 1% decline.
  • Earlier this month, Moderna secured EU approval for mCombriax (mRNA-1083), expanding its portfolio to four marketed products including two COVID-19 vaccines and an RSV vaccine.
  • The company's standalone flu shot, mRNA-1010, demonstrated superior efficacy compared with GSK's approved influenza vaccine, addressing previous concerns about mCombriax's flu component.
  • Moderna is developing more than 30 mRNA-based investigational candidates across different stages of clinical studies targeting various indications, including cancer.
  • Intismeran autogene, a personalized cancer therapy developed in collaboration with Merck MRK, is being evaluated in three pivotal phase III studies in melanoma and non-small cell lung cancer.
Risk Factors
  • Moderna is facing stiff competition from GSK and Pfizer in the RSV vaccine market, leading to expectations of minimal product sales for mResvia.
  • Analysts are projecting an earnings loss of $2.87 per share according to the Most Accurate Estimate, indicating ongoing profitability challenges.
  • Moderna's stock has rallied 65% year to date despite industry-wide declines, potentially inflating valuations ahead of earnings.
  • The company previously withdrew its initial mCombriax filing due to regulatory requests for additional efficacy data on the flu component, raising lingering concerns about FDA resubmission timelines.
  • Moderna's Earnings ESP is currently negative at -25.75%, signaling a lower probability of beating estimates compared to competitors like Agenus and Inovio.
  • The firm's Zacks Rank remains #3 (Hold), suggesting limited analyst confidence relative to top-rated peers with stronger buy recommendations.
  • While the company has approved its fourth marketed product, mCombriax faces an uncertain path to commercialization following a voluntary withdrawal and subsequent efficacy concerns.
Neutral 0

Moderna Gears Up to Report Q1 Earnings: Here's What to Expect - Zacks Investment Research

📅 Moderna reports Q1 2026 earnings May 1 ahead of opening bell.

💰 Revenue consensus $223.5M; EPS loss $2.29 improves year-over-year.

💉 Sales from COVID and RSV vaccines, though RSV outlook remains soft.

🔬 EU approved mCombriax flu vaccine after FDA resubmission focus.

📊 Shares up 65% YTD despite negative earnings surprise potential.

📅 Moderna is scheduled to report first-quarter 2026 earnings on May 1 before the opening bell.

📈 The company's last reported quarter saw earnings beat estimates by 18.85%, but this latest report does not predict a beat.

💰 Sales consensus estimate is pegged at $223.5 million, with earnings pinned at a loss of $2.29 per share, both showing improvement year-over-year.

💉 Product sales are expected to come from three marketed vaccines: two COVID-19 vaccines (Spikevax and mNexspike) and the RSV vaccine (mResvia).

⚠️ RSV vaccine sales outlook is soft due to stiff competition from GSK and Pfizer, leading to expectations of minimal product revenue for mResvia.

💊 Moderna secured EU approval for mCombriax, its first combination vaccine against COVID-19 and influenza, which marks the company's fourth marketed product.

🔬 The FDA resubmission timeline for mCombriax is expected to be a key focus after the filing was voluntarily withdrawn last year due to efficacy data requests.

⚖️ Moderna demonstrated superior efficacy for its standalone flu shot (mRNA-1010) compared to GSK's vaccine in late-stage data announced in June 2025.

🧬 The company has a pipeline of over 30 mRNA-based investigational candidates in various clinical stages targeting indications like cancer.

💊 Intismeran autogene, a personalized cancer therapy collaboration with Merck (MRK), is under evaluation in three pivotal phase III studies for melanoma and lung cancer.

📉 Year-to-date shares have rallied 65% against the industry's 1% decline, though current Earnings ESP stands at -25.75%.

🏆 Moderna has beaten earnings estimates for each of the trailing four quarters with an average surprise of 34.40%, but Zacks currently assigns a Rank #3 (Hold).

🚀 The article highlights Agenus and Inovio Pharmaceuticals as other stocks that meet specific criteria to potentially beat earnings expectations.

📊 Agenus (AGEN) has a +7.69% Earnings ESP and a Zacks Rank #1, with shares rising 30% year-to-date.

📉 Inovio (INO) shows a +3.33% Earnings ESP and a Zacks Rank #2, despite shares losing 33% year-to-date.

🔎 Readers are encouraged to use the Earnings ESP Filter to uncover other stocks with high odds of beating earnings before the report.

Bullish Signals
  • Moderna to report Q1 2026 earnings on May 1 with sales and earnings improvements.
  • Revenue from three marketed products including two COVID vaccines and one RSV vaccine.
  • Secured EU approval for mCombriax, the first combo vaccine targeting COVID and flu.
  • Standalone flu shot showed superior efficacy versus GSK approved influenza vaccine.
  • Developing over 30 mRNA candidates across various clinical study stages.
  • Intismeran autogene in three phase III studies for melanoma and lung cancer.
  • Beat estimates four consecutive quarters with average surprise of 34.40%.
  • Shares rallied 65% year to date versus industry decline.
Risk Factors
  • Moderna holds Zacks Rank #3 Hold vs. peers' Strong Buy ratings.
  • Earnings ESP negative at -25.75% for Q1 2026, likely missing estimates.
  • Analysts forecast $2.87 loss/share; prior quarter beat by 18.85%.
  • RSV vaccine mResvia faces stiff competition from GSK and Pfizer.
  • mCombriax filing withdrawn after FDA requested more flu data.
Bullish Signals
  • Moderna is scheduled to report first-quarter 2026 earnings on May 1 with both sales and earnings showing improvement over the year-ago period.
  • The company earned from three marketed products, including two COVID-19 vaccines (Spikevax and mNexspike) and an RSV vaccine (mResvia).
  • Moderna recently secured EU approval for mCombriax, its first combination vaccine targeting both COVID-19 and influenza.
  • The initial efficacy data for Moderna's standalone flu shot demonstrated superior performance compared with GSK's approved influenza vaccine.
  • Moderna is developing more than 30 mRNA-based investigational candidates across various stages of clinical studies, including targets for cancer.
  • Intismeran autogene, a personalized cancer therapy in partnership with Merck, is being evaluated in three pivotal phase III studies for melanoma and non-small cell lung cancer.
  • Moderna's performance has been impressive over the past four quarters, beating estimates each time with an average surprise of 34.40%.
  • Year to date, Moderna shares have rallied 65% against the industry's decline.
Risk Factors
  • Moderna faces a Zacks Rank #3, indicating Hold status, compared to Strong Buy ratings given by analysts for other biotech peers like Agenus and Inovio.
  • The Earnings ESP for Moderna is significantly negative at -25.75%, suggesting the company's earnings are likely to miss analyst expectations for Q1 2026.
  • Analysts estimate a loss of $2.87 per share, which contrasts with the previous quarter's performance where the company beat estimates by 18.85%.
  • The RSV vaccine mResvia is expected to have minimal product sales due to stiff competition from GSK and Pfizer's strong market foothold in that segment.
  • The combination vaccine mCombriax had its initial filing voluntarily withdrawn last year after the FDA requested additional efficacy data for the flu component.
  • Moderna currently carries a Zacks Rank #3, whereas peers Agenus and Inovio hold higher-ranked statuses of #1 Strong Buy and #2 Buy respectively.
Slightly Bullish +25

Moderna Gears Up to Report Q1 Earnings: Here's What to Expect

📈 Moderna beats 4 quarters with avg 34.4% surprise, Zacks predicts $2.29 loss estimate.

💰 Q1 sales expected $223.5M from COVID-19 and RSV vaccines despite RSV competition.

🚀 Shares rallied 65% year-to-date vs 1% industry decline as EU approves new combo vaccine.

📅 Moderna is scheduled to report Q1 2026 earnings results on May 1, before the market opens.

📊 The company beat estimates by 18.85% in the previous reported quarter with improving sales and loss metrics.

💰 Analysts expect product sales of roughly $223.5 million, primarily driven by two COVID-19 vaccines and one RSV vaccine.

⚠️ Revenue from the RSV vaccine mResvia is projected to be minimal due to strong competition from GSK and Pfizer.

🔬 Moderna secured EU approval earlier this month for mCombriax, a new combination vaccine against COVID-19 and influenza.

💉 The initial filing for mCombriax was withdrawn previously but late-stage data showed superior efficacy of the standalone flu component mRNA-1010.

🧬 The company is developing over 30 investigational candidates across various clinical stages, including cancer therapies.

🤝 A key pipeline highlight is intismeran autogene, a personalized cancer therapy being evaluated in three pivotal phase III studies with Merck.

📈 Moderna has beaten earnings estimates for the trailing four consecutive quarters with an average surprise of 34.40%.

🚀 Shares have rallied 65% year-to-date while the broader industry has seen a 1% decline.

⚙️ The Zacks Consensus Estimate predicts a loss of $2.29 per share for this quarter.

📉 Analysis indicates a probability of earnings miss based on current Earnings ESP metrics and stock rank.

Bullish Signals
  • Moderna beat earnings estimates by 34.40% over four quarters.
  • Shares rallied 65% year-to-date while industry fell 1%.
  • EU approved mCombriax, Moderna's fourth marketed product.
  • Flu shot mRNA-1010 outperformed GSK vaccine in late-stage data.
  • Pipeline has 30+ mRNA candidates across clinical stages.
  • Autogene therapy evaluated in three pivotal melanoma/lung cancer studies.
Risk Factors
  • Losses deepen to $2.87/share per The Most Accurate Estimate.
  • Earnings ESP at -25.75% signals high miss probability.
  • RSV vaccine faces stiff competition from GSK and Pfizer.
  • Revenue sustainability threatened by reliance on COVID-19 vaccines.
  • mCombriax filing withdrawn previously over FDA efficacy data requests.
  • Zacks Rank #3 Hold is less favorable than Strong Buy #1.
  • mCombriax requires FDA resubmission without guaranteed timeline.
Bullish Signals
  • Moderna earned strong momentum over the past four quarters, beating earnings estimates each time with an average surprise of 34.40%.
  • Year-to-date, Moderna's shares have rallied 65% against the industry's 1% decline.
  • Moderna secured approval in the EU for mCombriax (mRNA-1083), marking it as the fourth marketed product in the company's portfolio.
  • Moderna's standalone flu shot, mRNA-1010, demonstrated superior efficacy compared with GSK's approved influenza vaccine based on late-stage data announced in June 2025.
  • The pipeline includes more than 30 mRNA-based investigational candidates across different stages of clinical studies, including cancer indications.
  • Moderna is evaluating intismeran autogene, a personalized cancer therapy developed with Merck MRK, in three pivotal phase III studies targeting melanoma and non-small cell lung cancer.
Risk Factors
  • Operating losses are projected to deepen with a Zacks Consensus Estimate of a $2.29 per share loss for Q1, though The Most Accurate Estimate is pegged at an even deeper loss of $2.87.
  • The Earnings ESP stands at -25.75%, indicating high probability of missing analyst expectations and potential stock underperformance.
  • Moderna's RSV vaccine mResvia faces a softer outlook due to stiff competition from GSK and Pfizer, who have established strong footholds in the market.
  • A significant portion of product sales is expected to come from COVID-19 vaccines, raising concerns about post-pandemic revenue sustainability and demand fatigue.
  • The initial filing for mCombriax was voluntarily withdrawn last year after the agency requested additional efficacy data for the flu component, indicating previous regulatory hurdles.
  • Moderna currently carries a Zacks Rank #3 (Hold), which is less favorable compared to the Strong Buy (#1) or Buy (#2) recommendations preferred by investors.
  • The company's standalone flu shot demonstrated superior efficacy in June 2025, but mCombriax integration still requires FDA resubmission without a guaranteed timeline.
Neutral +5

Moderna Starts Large Bird Flu Study Despite Earlier HHS Funding Loss

🏥 Moderna launches US/UK clinical trial for bird flu mRNA vaccine in 4,000 adults.

💵 Company secured $54.3M after U.S. HHS cut pandemic funding amid political pressure.

✅ Earlier trials showed safety and effectiveness, positioning mRNA as critical pandemic tool.

📋 Moderna has initiated a large clinical trial for a bird flu mRNA vaccine in the United States and Britain.

👥 The study plans to enroll approximately 4,000 adults, with the first participants already receiving the shot.

🧬 The vaccine utilizes messenger RNA technology, similar to that used in COVID-19 vaccines.

✅ Earlier research involving 300 healthy adults demonstrated promising safety and immune response results.

⚠️ The trial had been delayed after the U.S. Department of Health and Human Services cut funding for pandemic flu vaccine development last year.

💰 Despite the HHS setback, Moderna secured up to $54.3 million from the Coalition for Epidemic Preparedness Innovations.

🎯 Moderna CEO Stéphane Bancel stated the trial is a critical step to strengthen global pandemic preparedness.

🗣️ The funding cuts followed questions from Trump administration officials regarding continued public funding for mRNA vaccines.

❌ HHS reduced mRNA vaccine funding citing that the technology remains under-tested for some uses and does not protect against mutating strains.

🔬 HHS officials claimed mRNA investments in upper respiratory viruses were wound down to reinvest in other more promising technologies.

🧬 Experts note that pandemic-era mRNA vaccines proved safe, effective, and faster to develop than traditional vaccines.

🦠 Additional resources on bird flu are available through Cornell University College of Veterinary Medicine.

📰 This news was reported by The Washington Post on April 21, 2026.

Bullish Signals
  • Moderna launched a bird flu vaccine trial with 4,000 participants across US and UK.
  • First study recipients received the shot, advancing pandemic preparedness.
  • Earlier research on 300 adults showed safety and strong immune response.
  • Moderna secured $54.3M from CEPIS after HHS funding setback.
  • CEO Stéphane Bancel highlights platform technology efficiency for future threats.
  • mRNA vaccines proved safe, effective and faster than traditional methods.
  • Officials acknowledge mRNA potential in cancer despite reduced HHS respiratory funding.
  • Large trial strengthens global pandemic preparedness against future outbreaks.
Risk Factors
  • Moderna secured $54.3M after losing HHS funding.
Bullish Signals
  • Moderna has initiated a large clinical trial for a bird flu vaccine with approximately 4,000 adult participants across the United States and Britain.
  • The first participants in this study have already received the vaccine shot, marking immediate progress in pandemic preparedness.
  • Earlier research involving about 300 healthy adults demonstrated promising results for both safety and immune response to the mRNA-based vaccine.
  • Despite a funding setback from HHS, Moderna secured $54.3 million from the Coalition for Epidemic Preparedness Innovations to support development.
  • Moderna CEO Stéphane Bancel emphasized that their platform technology's efficiency and scalability are critical for responding to future global health threats.
  • Experts noted that mRNA vaccines have proven to be safe and effective during the pandemic and can be developed more quickly than traditional vaccines.
  • Even though HHS reduced funding for upper respiratory viruses, officials acknowledged the potential for mRNA technology in other areas such as cancer.
  • The large clinical trial represents an important step toward strengthening global pandemic preparedness against future outbreaks.
Risk Factors
  • Moderna secured only $54.3 million from the Coalition for Epidemic Preparedness Innovations after losing HHS funding.
Neutral 0

Is Moderna (MRNA) Pricing Make Sense After 77% One-Year Surge And DCF Signal?

📉 Moderna stock surged 77% yearly but closed at $48.69 after recent declines.

💸 Free cash flow loss reached $2.19b over the last twelve months.

⚠ DCF model values shares at $22.87, implying current price is overvalued by 112.9%.

📉 Moderna's stock price has surged 77.3% over the last year but closed at $48.69 today after recent declines.

💸 The company recently reported a loss of approximately US$2.19b in free cash flow over the last twelve months.

🧮 A Discounted Cash Flow (DCF) model estimates Moderna's intrinsic value at US$22.87 per share.

⚠️ Based on the DCF analysis, Moderna appears to be overvalued by 112.9% compared to its current share price.

💹 The stock trades at a Price-to-Sales (P/S) ratio of 9.93x, which is higher than the company's proprietary Fair Ratio of 1.31x.

🏆 Moderna's P/S sits below the Biotechs industry average but remains above its specific peer group average.

📊 Simply Wall St identifies two contrasting investor narratives regarding Moderna's future fair value and risks.

💡 One optimistic narrative suggests a high fair value of US$175.00 based on potential pipeline success.

🐀 Another cautious narrative implies a low fair value near US$12.00 due to competitive pressure and regulatory concerns.

🦠 The cautious view highlights risks from reliance on specific vaccines and potential pricing policy changes.

🔬 The optimistic view emphasizes the company's mRNA pipeline, AI integration, and government contract opportunities.

📉 Both narratives agree that current sentiment is sharply divided regarding Moderna's post-pandemic value proposition.

🔄 The DCF model uses a two-stage free cash flow to equity method to project positive cash flows by 2030.

🏢 Simply Wall St rates Moderna just 1 out of 6 on their internal valuation checks indicating red flags.

Bullish Signals
  • Moderna gained 57.8% YTD and 77.3% over the last year.
  • Moderna trades at 9.93x P/S, below Biotechs average of 10.95x.
  • Bullish fair value estimate of US$175 implies 72.2% undervaluation.
  • Many pipeline products in motion offer significant upside potential.
  • Clean balance sheet trades below book value with reinvestment.
  • Cost cuts and AI support expanding mRNA pipeline growth.
  • DCF projects US$241.7m Free Cash Flow by 2030.
  • Post-pandemic pullback framed as overreaction to declining COVID revenue.
  • Revenue growth of 48.43% supports bullish fair value of US$175.
Risk Factors
  • Moderna lost US$2.19B in free cash flow with negative projections continuing.
  • DCF model shows Moderna stock is 112.9% overvalued at US$48.69 vs intrinsic US$22.87.
  • Price-to-Sales ratio of 9.93x exceeds the fair ratio of 1.31x significantly.
  • Company relies on few vaccines, regulatory scrutiny, and pricing policy constraints.
  • External partners needed for funding high-cost programs raise capital efficiency concerns.
  • Competitive pressure and regulatory shifts threaten future growth prospects materially.
  • Stock declined 10.8% last week with a 63.5% drop over three years.
Bullish Signals
  • Moderna has gained 57.8% year to date and 77.3% over the last year, demonstrating significant recent momentum despite short-term declines.
  • The company trades on a P/S ratio of 9.93x, which is below the Biotechs industry average of 10.95x, suggesting room for multiple expansion relative to the broader sector.
  • A bullish narrative estimates fair value at US$175.00, implying approximately 72.2% undervaluation compared to the recent share price of US$48.69.
  • Moderna is viewed as a biotech company with many pipeline products already in motion and potential upside if even a handful of programs succeed.
  • The company emphasizes its clean balance sheet while trading below book value, supported by years of reinvestment into its pipeline.
  • Cost cuts, AI use, and government contracts are highlighted as positive catalysts that could support an expanding mRNA pipeline.
  • Moderna's DCF model projects Free Cash Flow turning to about US$241.7m by 2030, indicating strong long-term cash generation potential once the transition from losses is complete.
  • The company frames the post-pandemic share price pullback as an overreaction to declining COVID revenues, suggesting a re-rating opportunity if future pipelines succeed.
  • Simply Wall St offers two leading Narratives for Moderna, with one bullish scenario projecting revenue growth of 48.43% and fair value at US$175.00.
Risk Factors
  • Moderna reported a twelve-month loss of US$2.19 billion in Free Cash Flow, with analysts projecting continued negative cash flow for several years.
  • According to the Discounted Cash Flow model, Moderna's stock is estimated to be 112.9% overvalued relative to its intrinsic value of US$22.87 per share against a recent price of US$48.69.
  • The company trades at a Price-to-Sales ratio of 9.93x, which exceeds the proprietary Fair Ratio of 1.31x suggested by Simply Wall St's valuation model.
  • A significant portion of community narratives highlight risks including reliance on a few key vaccines, potential regulatory scrutiny, and pricing policy constraints.
  • Concerns are raised regarding the need for external partners to fund high-cost programs, suggesting capital efficiency issues and dependency on third parties.
  • Competitive pressure and shifting regulatory landscapes are explicitly cited as headwinds that could impact future growth prospects.
  • The stock has experienced a 10.8% decline over the last 7 days and a 3 year return decline of 63.5%, indicating recent price volatility and long-term underperformance.
Slightly Bullish +25

CureVac files Covid-19 vaccine lawsuit against Moderna - CDR News

🔬 CureVac sued Moderna in Delaware on April 24, 2026 for patent infringement.

⚖ The lawsuit seeks royalty recovery from Moderna's Covid-19 vaccine profits.

⚠ Dispute centers on mRNA technology used in pandemic-era vaccines.

🔬 CureVac, a German biotech company, has filed a lawsuit against Moderna in the US District Court for the District of Delaware.

⚖️ The legal action was filed on April 24, 2026, alleging infringement of patented innovations related to Covid-19 vaccine therapeutics.

💰 CureVac is seeking recovery of royalties from Moderna's profits generated by its Covid-19 vaccines.

👥 The German company is requesting a jury trial as part of its legal demand against the pharmaceutical giant.

⚠️ This lawsuit centers on intellectual property disputes regarding mRNA technology specifically used in pandemic-era vaccines.

📅 The article was published on April 27, 2026, by Natasha Doris for CDR News.

🏢 Moderna is described as a major pharmaceutical entity being targeted by the German biotech firm's claims.

Bullish Signals
  • CureVac sued Moderna over patented mRNA innovations.
  • The lawsuit was filed on April 24, seeking jury trial and damages.
  • CureVac is challenging mRNA market competition through IP.
Risk Factors
  • CureVac sued Moderna in Delaware over mRNA patent infringement.
  • Lawsuit filed April 24, 2026, seeks royalties from Covid-19 vaccines.
  • Moderna faces IP accusations that could disrupt operations.
Bullish Signals
  • CureVac filed a lawsuit against Moderna in the US District Court for the District of Delaware, asserting its patented mRNA therapeutics innovations. This legal action could secure royalty recovery from Moderna's profits related to Covid-19 vaccines.
  • The filing was submitted on 24 April 2026, with CureVac requesting a jury trial and damages based on patent infringement claims.
  • CureVac is leveraging its intellectual property portfolio to challenge market competition in the mRNA sector.
Risk Factors
  • German biotech CureVac has filed a lawsuit against pharmaceutical giant Moderna in the US District Court for the District of Delaware, alleging infringement on patented innovations for mRNA therapeutics.
  • The lawsuit, filed on April 24, 2026, demands a jury trial and recovery of royalties from Moderna's profits garnered from its Covid-19 vaccines, potentially exposing Moderna to significant financial liabilities.
  • Moderna faces direct intellectual property accusations regarding its Covid-19 vaccine development, which could disrupt its commercial operations and create legal precedents affecting other mRNA therapeutics.
Slightly Bullish +25

CureVac takes Moderna to court over mRNA vaccine patents - European Biotechnology Magazine

📉 CureVac sued Moderna alleging patent infringement over Spikevax mRNA vaccine technology.

💰 The company seeks royalties from Spikevax sales without authorization for its proprietary tech.

⚠ This IP dispute reflects broader competition in the lucrative mRNA vaccine ecosystem.

📉 CureVac has filed a federal lawsuit against Moderna alleging patent infringement over the mRNA-based COVID-19 vaccine Spikevax.

💰 The German biotech company seeks monetary damages in the form of royalties based on a share of Spikevax sales.

🧬 CureVac claims Moderna utilized its proprietary mRNA-stabilisation and delivery technologies without authorization.

⚖️ This case is part of a broader trend where companies like Bayer are pursuing revenue shares from established COVID-19 vaccine makers through patent actions.

🏗️ BioNTech, CureVac's parent company at the time of filing, previously sued Moderna regarding its next-generation mNEXSPIKE shot separately.

🛡️ Moderna has acknowledged the complaint and vowed to defend itself by stating its vaccine portfolio relies on internally developed know-how.

🚀 CureVac’s lawsuit marks an aggressive IP monetisation strategy as it leverages legacy patents acquired through BioNTech rather than relying solely on Pfizer partnerships.

🏢 BioNTech acquired CureVac (now referred to as part of the larger German biotech group) to consolidate a strong mRNA IP portfolio for litigation leverage.

💉 This legal dispute highlights the competitive intensity within the mRNA ecosystem following the multibillion-dollar success of recent vaccines.

⚡️ The Unified Patent Court is noted as a mechanism intended to facilitate such cross-border patent litigation across Europe.

Bullish Signals
  • CureVac seeks royalty payments on Moderna's vaccine sales.
  • BioNTech combines IP portfolios to strengthen patent enforcement.
  • Acquisition integrates mRNA methods with Pfizer-BioNTech platform.
  • Phase II data advances oncology pipeline beyond vaccines.
  • European court streamlined for faster, affordable patent litigation.
Risk Factors
  • CureVac sues Moderna over Spikevax patent infringement.
  • Moderna defends, claiming vaccine uses internal knowledge.
Bullish Signals
  • CureVac is pursuing monetary damages framed as royalties on Moderna's Spikevax sales, indicating strong revenue upside potential from high-volume vaccine production.
  • BioNTech has strengthened its position by integrating CureVac's legacy mRNA IP portfolio with one of the most successful COVID-19 vaccine developers, enhancing leverage to enforce patents across the mRNA ecosystem.
  • The acquisition of CureVac in 2025 placed its proprietary methods for stabilising messenger RNA under the same roof as BioNTech, directly boosting the value of the Pfizer-BioNTech Comirnaty platform.
  • BioNTech has presented compelling Phase II data for its compound trastuzumab pamirtecan, advancing its pipeline beyond COVID-19 vaccines into high-value oncology treatments like advanced uterine cancer.
  • The Unified Patent Court has been established to make patent litigation in Europe easier, faster and more affordable, providing a streamlined framework for capturing value from mRNA innovation.
Risk Factors
  • CureVac has filed a federal lawsuit accusing Moderna of patent infringement over its mRNA-based COVID-19 vaccine Spikevax, seeking monetary damages framed as royalties on sales.
  • Moderna has acknowledged the complaint and stated it will defend itself vigorously, arguing that its COVID-19 vaccine portfolio is built on internally developed know-how and does not infringe CureVac's patents.
Somewhat Bullish +45

BioNTech’s Double Play: Cancer Vaccine Milestone and a New Legal Front Against Moderna

🩺 Autogene Cevumeran showed 87.5% six-year survival for immune responders in pancreatic cancer patients.

⚖ CureVac sued Moderna over mRNA stabilization technology, seeking licensing fees in Delaware court.

📈 BioNTech shares rose 16% despite lower revenue forecast, with analysts maintaining Moderate Buy rating.

🎯 Company targets oncology revenue post-2026 and aims to become multi-product by 2030.

📅 Key dates include May 5 results release and supervisory board expansion proposal.

📊 BioNTech's personalized mRNA cancer vaccine, Autogene Cevumeran (BNT122), showed a striking six-year survival rate of 87.5% in pancreatic cancer patients who mounted an immune response.

🏥 Among non-responders to the vaccine, only 25% survived the same period with a median overall survival of 3.4 years.

⏳ The T-cells triggered by the vaccine have an estimated average lifespan of 7.7 years, suggesting potential for long-term immunological surveillance against cancer recurrence.

🧬 Each dose is custom-manufactured based on a patient's tumor DNA profile, encoding up to 20 patient-specific neoantigens.

⚖️ BioNTech's subsidiary CureVac filed a patent infringement lawsuit in Delaware federal court against Moderna regarding Spikevax mRNA stabilization technology.

💰 The German biotech group is seeking licensing fees from Moderna as part of the legal dispute over intellectual property.

📉 BioNTech shares closed Friday at €88.75, up roughly 16% over the past month despite a recent lowered 2026 revenue forecast.

📈 Wall Street analysts rate BioNTech shares with a consensus "Moderate Buy" rating and an average price target of $133.

🚀 The company is targeting 15 Phase 3 oncology studies running by the end of 2026, with up to seven late-stage clinical data packages expected this year.

🎯 Meaningful oncology revenue is not anticipated until after 2026, but the goal of becoming a multi-product oncology company by 2030 remains intact.

🗓️ Investors should note first-quarter results due on May 5 and an annual general meeting proposal to expand the supervisory board to eight members.

Bullish Signals
  • Seven of eight patients survived six years post-surgery with personalized mRNA cancer vaccine.
  • 87.5% of responders alive at last follow-up versus non-responders.
  • T-cells triggered by vaccine have average lifespan of 7.7 years.
  • Global Phase 2 trial underway after positive Phase 1 data.
  • Shares rallied nearly 19% over past 30 days trading above €88.75.
  • Eighteen analysts rate BioNTech Moderate Buy with €133 target.
  • Company targeting 15 Phase 3 oncology studies by end of 2026.
  • Aims to become multi-product oncology company by 2030.
  • Expanding governance with eight-member supervisory board vote in May.
Risk Factors
  • BioNTech lowered 2026 revenue forecast.
  • Founders depart year-end, creating uncertainty.
  • Stock trades below €101.90 high.
  • Unresolved Moderna lawsuit poses liabilities.
  • Oncology revenue unlikely until post-2026.
  • Supervisory board expansion vote signals instability.
Bullish Signals
  • BioNTech reported a striking seven-year survival milestone with its personalized mRNA cancer vaccine Autogene Cevumeran, where seven out of eight patients remained alive six years after surgery for pancreatic ductal adenocarcinoma.
  • Among responders to the personalized mRNA cancer vaccine, 87.5% of patients were still alive at the last follow-up, compared to a much lower survival rate in non-responders.
  • The T-cells triggered by BioNTech's vaccine carry an estimated average lifespan of 7.7 years, suggesting the mRNA approach could enable long-term immunological surveillance against cancer recurrence.
  • A global Phase 2 trial for Autogene Cevumeran is already underway following positive Phase 1 data presented at the AACR Annual Meeting 2026.
  • BioNTech shares have rallied nearly 19 percent over the past 30 days, trading above its closely watched 200-day moving average at €88.75.
  • Eighteen analysts rate BioNTech shares a consensus 'Moderate Buy' with an average price target of $133.
  • The company is targeting 15 Phase 3 oncology studies running by the end of 2026, with up to seven late-stage clinical data packages expected this year.
  • BioNTech aims to become a multi-product oncology company by 2030, maintaining its long-term growth strategy despite recent founder departures.
  • The company is expanding corporate governance with a proposal to put an eight-member supervisory board to a vote at the annual general meeting in May.
Risk Factors
  • BioNTech recently lowered its 2026 revenue forecast, indicating weaker near-term financial prospects.
  • Both founders of the company are departing at year-end, creating significant leadership and strategic uncertainty for investors.
  • The stock trades well below its 52-week high of €101.90, suggesting continued bearish sentiment or undervalued performance despite recent gains.
  • BioNTech faces ongoing unresolved legal disputes, including Moderna's 2022 lawsuit over Comirnaty that remains unsettled, posing potential long-term financial liabilities.
  • Meaningful oncology revenue is not anticipated until after 2026, leaving the company reliant on COVID vaccine income in the near term while competing against other pharma heavyweights for historic revenue streams.
  • A proposal to expand the supervisory board from seven to eight members will be voted on at the annual general meeting, which could signal internal governance instability or need for external expertise.
Neutral 0

Analysts Offer Insights on Healthcare Companies: Praxis Precision Medicines (PRAX) and Moderna (MRNA)

📈 Analyst maintains Buy on Praxis with $567 target vs current price of $344.

💰 Shares trade at 89% below consensus but FDA accepted NDA for ulixacaltamide.

⚠ Wall Street consensus on Moderna is Hold with average price target of $38.43.

📈 Analyst Francois Brisebois from LifeSci Capital maintains a Buy rating on Praxis Precision Medicines with a $567.00 price target.

💰 Praxis shares closed at $344.82, reflecting an 89.2% upside to the analyst consensus price target of $625.31.

⭐ The current consensus for Praxis is Strong Buy with a success rate of 40.4% among Brisebois’s previous calls.

🔄 TipRanks previously upgraded Praxis to Buy on April 15, though Deutsche Bank later raised its target from $412 to $437.

📉 William Blair analyst Myles Minter reiterated a Hold rating for Moderna despite shares closing at $50.73 near their 52-week low of $29.25.

⚠️ Street consensus on Moderna is Hold with an average price target of $38.43, implying a -28.0% downside from current levels.

🔬 Bernstein maintained its Hold rating on Moderna on April 21 with a $45.00 price target to support the neutral sentiment.

💊 Praxis Precision Medicines is advancing its CNS pipeline including an NDA for Ulixacaltamide in Essential Tremor.

✅ The FDA accepted Praxis’s NDA for ulixacaltamide, providing a near-term data catalyst mentioned by analysts.

📊 LifeSci Capital suggests that near-term data and pipeline advancement support the Buy rating despite company cash burn.

Bullish Signals
  • LifeSci Capital maintains Buy rating on PRAX with $567 target vs. $345 current price.
  • Analyst consensus Strong Buy implies 89% upside from current levels.
  • TipRanks upgraded PRAX to Buy with $381 target, signaling growing confidence.
  • William Blair analyst Myles Minter is a 5-star analyst covering Moderna.
  • Deutsche Bank raised PRAX price target to $437 reflecting positive sentiment.
  • FDA accepted ulixacaltamide NDA for Essential Tremor supporting pipeline advancement.
  • Strong Buy ratings from Raymond James support advancing CNS Pipeline and data catalysts.
Risk Factors
  • Analyst Myles Minter maintains Hold rating on Moderna.
  • Street consensus is Hold with $38.43 target implying 28% downside.
  • Shares at $50.73 near 52-week low of $29.25.
Bullish Signals
  • Francois Brisebois from LifeSci Capital maintained a Buy rating on Praxis Precision Medicines (PRAX) with a price target of $567.00, which represents significant upside potential from the current share price of $344.82.
  • The analyst consensus on Praxis Precision Medicines is a Strong Buy with an average price target of $625.31, implying an 89.2% upside from current levels.
  • TipRanks upgraded PRAX to Buy with a $381.00 price target in a report issued on April 15, signaling growing confidence in the stock's performance.
  • William Blair analyst Myles Minter is a 5-star analyst with an average return of 35.4% and a 58.7% success rate, covering Moderna (MRNA).
  • Deutsche Bank raised its Praxis Precision price target to $437 from $412, reflecting positive sentiment among major investment banks.
  • Praxis Precision Medicines received FDA acceptance for ulixacaltamide NDA for Essential Tremor, a key milestone supporting its pipeline advancement.
  • The company is supported by recent Strong Buy ratings from Raymond James and other analysts due to advancing CNS Pipeline and near-term data catalysts.
Risk Factors
  • William Blair analyst Myles Minter reiterated a Hold rating on Moderna today, indicating cautious sentiment from Wall Street.
  • The word on The Street generally suggests a Hold analyst consensus rating for Moderna with a $38.43 average price target, implying a 28.0% downside from current levels.
  • Moderna shares closed last Friday at $50.73, close to its 52-week low of $29.25, suggesting recent significant price weakness and loss of momentum.
Somewhat Bearish -25

Moderna shares slide as traders digest recent EU vaccine clearance and refocus on funding/earnings overhangs - Quiver Quantitative

📉 Moderna shares dropped 4% after EU vaccine approvals raised cash burn concerns.

💸 Influenza program uncertainty persists amid reduced U.S. government support.

🧠 Insiders sold stock four times in six months without any purchases.

🎯 Analysts target $30/share, split with one buy and two sell ratings.

📉 Moderna shares fell 4.0% today as traders digested recent European regulatory approvals.

➖ Investor focus has shifted back to near-term cash burn concerns after the EU vaccine clearance news.

🏥 Market attention is now refocusing on earnings and potential funding overhangs for ongoing programs.

💸 Uncertainty remains regarding influenza program advancement due to reduced U.S. government support.

🧠 Insiders have sold Moderna stock 4 times in the past six months with no purchases recorded.

📊 Institutional investors showed mixed activity, adding shares for 286 investors but reducing positions for 318 investors last quarter.

👨‍💼 Wall Street analyst sentiment is neutral to negative, with two sell ratings issued alongside one buy rating recently.

🎯 Eleven analysts have provided price targets over the last six months, settling on a median target of $30.00 per share.

⚠️ The price pullback suggests investors are weighing financial implications of shifting funding sources and timelines.

🔍 Market data indicates potential caution from major holders as regulatory headwinds subside.

Risk Factors
  • Shares down 4% amid cash burn and earnings focus.
  • Funding uncertain as U.S. support reduced for flu programs.
  • Insiders sold 4 times in 6 months vs zero purchases.
  • 318 institutions cut holdings vs only 286 added shares.
  • Wall Street mixed: 2 sell ratings vs 1 buy rating.
Risk Factors
  • Moderna shares dropped 4.0% today as investor attention shifted from recent European regulatory wins back to near-term cash burn and upcoming earnings.
  • There is uncertainty around funding and timelines as Moderna advances certain influenza programs despite reduced U.S. government support.
  • Insider trading data shows a concerning trend with insiders selling the stock 4 times in the past 6 months versus making zero purchases.
  • Institutional investors are reducing their positions, with 318 decreasing their holdings while only 286 added shares in the most recent quarter.
  • Wall Street sentiment is mixed or negative, with 2 firms issuing sell ratings compared to only 1 firm issuing buy ratings.
Somewhat Bearish -25

Moderna (MRNA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release - Yahoo Finance

📅 Moderna reports quarterly results expected on May 1, with EPS loss of $2.28 projected.

💰 Revenue forecasted at $223.47 million, a 106.9% year-over-year increase.

⚠ Negative Earnings ESP limits predictive accuracy despite four historical beat streaks.

📅 Moderna (MRNA) is expected to report quarterly results for the quarter ended March 2026, with earnings anticipated on May 1.

📉 Analysts predict a year-over-year EPS increase of 9.5%, expecting a quarterly loss of $2.28 per share.

💰 Revenue is forecasted at $223.47 million, representing a significant 106.9% increase from the same quarter last year.

📊 Consensus EPS estimates have been revised slightly upward by 0.22% over the past 30 days due to analyst reassessments.

⚠️ The Zacks Earnings ESP for Moderna is -36.40%, indicating the Most Accurate Estimate is lower than the consensus.

🤖 A negative Earnings ESP suggests difficulty in predicting an earnings beat, as predictive power is limited with negative readings.

⭐ Moderna currently holds a Zacks Rank of #3 (Hold), which combined with the negative ESP makes it a non-compelling candidate for beating estimates.

📈 Historical data shows Moderna beat consensus EPS estimates four times over the last four quarters, including an 18.85% surprise in the prior quarter.

⚖️ Stock price movements are not solely dependent on earnings surprises and can be influenced by other undisclosed factors or catalysts.

🔍 This analysis contrasts with Amgen (AMGN), which also has a negative Earnings ESP (-1.28%) but maintains a Zacks Rank of #3.

📉 Amgen's consensus EPS estimate was revised 1% up over the last 30 days, with revenue expected to rise 4.2%.

🏆 Amgen has beaten consensus EPS estimates in each of its trailing four quarters compared to Moderna's historical beat record.

📚 The Zacks Earnings ESP Filter can help investors identify stocks likely to beat estimates before quarterly releases.

💼 Both Moderna and Amgen reports are available for review via free stock analysis reports provided by Zacks Investment Research.

📅 Investors are encouraged to consult the Zacks Earnings Calendar for upcoming earnings announcements across the industry.

Bullish Signals
  • Moderna revenues expected at $223.47M Q1 2026, up 106.9% YoY.
  • Consensus EPS estimate revised up 0.22% in last 30 days.
  • Moderna beat estimates for four consecutive quarters historically.
  • Company delivered +18.85% earnings surprise with -$2.11 vs -$2.60.
  • Zacks Rank #3 (Hold) supports investment opportunity assessment.
Risk Factors
  • Analysts downgrade Moderna, forecasting -36.40% earnings ESP for May 1.
  • Zacks Rank #3 and negative ESP make a beat unlikely for Q1 2026.
  • Company expects $2.28 quarterly loss amid sustainability concerns despite revenue growth.
  • Recent bearish sentiment raises downside risk if results miss expectations.
Bullish Signals
  • Moderna is expected to report revenues of $223.47 million for the quarter ended March 2026, representing a significant 106.9% year-over-year increase from the prior period.
  • The consensus EPS estimate for Moderna has been revised upward by 0.22% over the last 30 days, reflecting growing analyst confidence in the company's earnings prospects.
  • Moderna has demonstrated a strong historical track record of beating consensus estimates, having exceeded expectations in each of its last four quarters.
  • The company previously delivered a positive earnings surprise of +18.85% by reporting a loss of -$2.11 per share instead of the expected -$2.60 per share.
  • Investors can utilize Moderna's Zacks Rank of #3 (Hold) alongside its recent performance history as a favorable factor for assessing upcoming market opportunities.
Risk Factors
  • Analysts have recently become bearish on Moderna's earnings prospects, resulting in a negative Earnings ESP of -36.40% ahead of the May 1 earnings release.
  • A combination of negative Earnings ESP and a Zacks Rank of #3 makes it difficult to predict that Moderna will beat the consensus EPS estimate for the quarter ended March 2026.
  • The expected quarterly loss of $2.28 per share indicates the company is still unprofitable, with investors focused on sustainability concerns despite revenue growth.
  • While the stock historically beats earnings estimates in four out of the last four quarters, recent bearish sentiment suggests potential downside risk if actual results fail to meet market expectations.
Bullish +75

Moderna’s combo flu-COVID vaccine receives European authorization - CIDRAP

💉 EU Commission approves Moderna's first flu-COVID combination vaccine, mCombriax.

🧬 Single-dose formula combines existing COVID-19 and investigational flu technologies.

✅ Phase 3 trials confirmed strong immunity with no major safety concerns.

🌍 Authorization covers all 27 EU member states plus EEA nations.

🗣 CEO Bancel aims to simplify immunization and strengthen healthcare resilience.

🩸 Moderna's first combination seasonal flu-COVID vaccine, mCombriax, received marketing authorization from the European Commission.

💉 The approval follows a positive review by the European Medicines Agency’s Committee for Medicinal Products for Human Use.

🗣️ Moderna CEO Stephane Bancel stated the single-dose vaccine aims to simplify immunization and strengthen healthcare system resilience in Europe.

🧬 mCombriax builds on Moderna's existing COVID-19 vaccine (mNexspike) and investigational flu vaccine (mRNA-1010), both widely reviewed globally.

💪 Phase 3 trials showed significant immune responses against three influenza strains and SARS-CoV-2 in adults aged 50 to 64 and 65+.

⚠️ No major safety concerns or adverse events were observed during the phase 3 trial period.

🌍 The marketing authorization applies to all 27 EU member states plus Iceland, Liechtenstein, and Norway.

Bullish Signals
  • Moderna's flu-COVID vaccine received EU marketing authorization.
  • Phase 3 trials showed higher immune responses in adults 50+.
  • CEO Bancel says vaccine simplifies immunization for high-risk adults.
  • Authorization valid across all 27 EU member states and EEA.
  • No major safety concerns observed in the phase 3 trial.
Risk Factors
  • CDC blocked vaccine efficacy report, raising transparency concerns.
  • Paxlovid trial shows no benefit for vaccinated outpatients.
  • RFK Jr delays $600 million foreign vaccine shipments.
  • RFK Jr claims no measles responsibility amid spread fears.
  • Hegseth removed flu mandate for troops, risking herd immunity.
  • Survey shows 70% distrust medical science, hindering public health.
  • Wild bird virus notices dropped to 13 in past 10 days.
  • Total marine mammals with H5N1 in California reached 58.
Bullish Signals
  • Moderna's mCombriax combination flu-COVID vaccine has received marketing authorization from the European Commission after a positive review by the European Medicines Agency's Committee for Medicinal Products for Human Use.
  • The vaccine performed well in a phase 3 trial, eliciting statistically significant higher immune responses against three influenza virus strains and SARS-CoV-2 in adults aged 50 to 64 years and 65 years and older.
  • Moderna CEO Stephane Bancel stated the combination vaccine aims to simplify immunization for high-risk adults while strengthening healthcare system resilience across Europe.
  • The marketing authorization is valid in all 27 EU member states, as well as Iceland, Liechtenstein, and Norway.
  • No major safety concerns or adverse events were observed in the phase 3 trial of mCombriax.
Risk Factors
  • CDC blocks publication of a report showing COVID vaccine efficacy, raising concerns about transparency and potential suppression of critical data.
  • Paxlovid trial results show the drug does not reduce hospitalization or death rates in vaccinated high-risk outpatients, limiting its efficacy for this demographic.
  • RFK Jr is holding up distribution of $600 million in vaccines to foreign nations, according to a report.
  • In hearings, RFK Jr claims no responsibility for measles spread despite ongoing concerns about the virus.
  • Hegseth removes flu vaccination requirement for US troops by calling mandates overly broad, potentially reducing herd immunity levels.
  • Seven in 10 people surveyed hold at least one view against medical science, indicating a significant misinformation challenge to public health initiatives.
  • Wild bird detections have dropped to just 13 notices from APHIS in the past 10 days, suggesting shifting epidemiological patterns that complicate tracking.
  • Eleven more marine mammals confirmed to have H5N1 avian flu in California brings the total to 58, with 57 sea lions and one otter affected.
Bullish +75

Moderna wins EU nod for combined COVID, flu shot (MRNA:NASDAQ) - Seeking Alpha

📅 European Commission granted marketing authorization for Moderna's mCOMBRIAX vaccine on April 21, 2026.

💉 mRNA-1083 is a single-dose messenger RNA vaccine targeting influenza and SARS-CoV-2 simultaneously.

🌍 The approval applies specifically to the European Union market distribution.

📅 On April 21, 2026, the European Commission issued marketing authorization for Moderna's mCOMBRIAX vaccine.

💉 The approved product, mRNA-1083 (mCOMBRIAX), is a single-dose messenger RNA-based vaccine.

🦠 The vaccine targets two pathogens simultaneously: influenza and SARS-CoV-2 to prevent COVID-19 and flu disease.

📜 This authorization follows the European Commission's regulatory review and approval process for the combined shot.

🏢 Moderna, Inc. (NASDAQ: MRNA) announced the news on Tuesday via its official press release.

🌍 The approval applies specifically to the European Union market for the distribution of mCOMBRIAX.

📈 This development represents a significant milestone for Moderna's portfolio beyond its original COVID-19 vaccine.

👨‍⚕️ Clinical trials and safety data must have supported the single-dose efficacy against both respiratory viruses.

💼 The approval positions mCOMBRIAX as an alternative to sequential vaccination approaches requiring multiple shots.

Bullish Signals
  • Moderna got European Commission approval for its dual-dose mRNA-1083 vaccine.
  • This opens a new market opportunity in Europe for two respiratory illnesses.
  • The approval shows strong performance of Moderna's mRNA technology.
  • European clearance strengthens credibility for other regional filings.
Risk Factors
  • Article focuses only on approvals, ignoring risks.
  • Lacks data on stock, revenue, or competition.
Bullish Signals
  • Moderna received marketing authorization from the European Commission for mCOMBRIAX (mRNA-1083), its single-dose vaccine targeting both COVID-19 and influenza.
  • This regulatory approval opens up a significant new market opportunity for Moderna in Europe by combining protection against two major respiratory illnesses.
  • The clearance of the mRNA-1083 vaccine demonstrates the continued strong performance and efficacy of Moderna's messenger RNA platform technology.
  • Securing approval from the European Commission, a key global regulator, strengthens Moderna's credibility and positions the company favorably for potential filings in other regions.
Risk Factors
  • The article is entirely focused on positive regulatory approval news without highlighting any associated risks or negative aspects.
  • No specific data points regarding stock performance, revenue impact, or competitive threats are mentioned in this announcement.
Somewhat Bullish +42

Moderna lines up melanoma and myeloma data for ASCO in Chicago - Stock Titan

⚠ No valid news article content was found on the provided link.

🔍 Financial data and quotes are missing from the source material.

📄 The text indicates a website error preventing access to Moderna information.

⚠️ The provided article text is a website error message rather than news content about Moderna or mRNA.

🔍 No specific data, quotes, dates, or financial facts are available for summarization from the source material.

📄 The only identifiable entity mentioned in the text is the stocktitan.net domain attempting to load news that could not be retrieved.

Bullish Signals
  • No extractable positive points found.
  • Input is a browser error message.
Risk Factors
  • Connection timeout indicates server instability.
  • Investors cannot verify ASCO data due to technical issues.
Bullish Signals
  • The provided text appears to be a browser error message indicating the website could not be reached (ERR_CONNECTION_TIMED_OUT), rather than containing actual news content about Moderna. No positive points regarding mRNA can be extracted from this technical error response.
Risk Factors
  • The website hosting this news article could not be reached due to a connection timeout (ERR_CONNECTION_TIMED_OUT), indicating potential server instability or accessibility issues for StockTitan.
  • Technical difficulties preventing access to the actual content mean investors cannot verify the accuracy of the data presented at ASCO or confirm Moderna's clinical progress in melanoma and myeloma programs.